Can you compare clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab?

Can you compare clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab?

Can you compare, based on published RA trials, both the clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab? And how do these outcomes in RA patients treated with this or other biosimilars compare to effectiveness and adverse effects reported for the reference biologic, infliximab?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas